SLS — SELLAS Life Sciences Group, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1390478 ·
Last close
$19.15
Market Cap
$3.90B
52W High
$24.89
52W Low
$1.39
ADV30
10,839,478
Next earnings
—
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -11,309,000 -10,091,000 141,091,000 134,711,000 9,286,000
Jun 2026 0 — -10,629,000 -9,605,000 145,382,000 138,343,000 7,726,000
Mar 2026 0 — -9,252,000 -8,407,000 114,177,000 107,097,000 6,765,000
Dec 2025 0 — -8,255,000 -7,658,000 78,345,000 71,793,000 7,474,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-28,423,000
Investing CF
—
Financing CF
$141,469,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.23
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-293,000,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-35,219,000
Pretax Income TTM
$-32,461,000
Interest Exp TTM
—
Analysts
2

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -28,274,000 -26,863,000 78,345,000 7,474,000 70,871,000 -28,389,000
Dec 2024 0 -31,513,000 -30,881,000 19,432,000 9,967,000 9,465,000 -35,402,000
Dec 2023 0 -37,869,000 -37,340,000 6,219,000 14,195,000 -7,976,000 -31,410,000
Dec 2022 1,000,000 -31,950,000 -41,301,000 20,943,000 16,092,000 4,851,000 -23,809,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$37,468,000
NetIncome TTM
$-32,461,000
OpCashFlow TTM
—
Assets (Latest)
$145,382,000
Forward EPS
$-0.20

Peers — same industry

TickerNameMarket CapLastDaily %
XENE Xenon Pharmaceuticals Inc. $3.81B $38.78 —
TNGX Tango Therapeutics, Inc. $3.75B $22.11 —
OGN Organon & Co. $3.65B $13.90 —
ABCL AbCellera Biologics Inc. $3.60B $11.03 —
INDV Supernus, Inc. $4.28B $36.28 —

News headlines (Yahoo Finance, 1h cache)

SLS Joins MRNA And ANL In Biotech’s Top 3 This Year — Here’s How A Late-2025 Bet Could Grow 10x From Here
2026-11-18 02:41 · Yahoo
SELLAS Stock In Focus After Phase 3 AML Trial Win
2026-11-18 00:18 · Yahoo
Sellas Life Sciences stock falls on $150M stock offering
2026-11-17 22:17 · Yahoo
Another Cancer Vaccine Just Scored A Home Run; Shares Catapult 150%
2026-11-17 21:33 · Yahoo
SELLAS Life Sciences Announces Proposed $150.0 Million Underwritten Public Offering
2026-11-17 21:01 · Yahoo
Sellas Life Sciences shares surge 175% after cancer vaccine succeeds in late-stage trial
2026-11-17 16:20 · Yahoo
SELLAS Life Sciences stock soars 240% on positive cancer trial
2026-11-17 14:12 · Yahoo
Sellas’ GPS Cuts Death Risk By 41% In Pivotal AML Trial – Firm Eyes FDA Filing In First Half Of 2027
2026-11-17 12:59 · Yahoo
SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically Significant and Clinically Meaning
2026-11-17 12:00 · Yahoo
SLS Stock Jumps After-Hours: Retail Eyes Lilly’s Cancer Deal for Valuation Clues — 2 Big Investors Grab Shares
2026-11-17 01:54 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.